Slingshot InsightsQ2 2018 Biotech Catalyst Watchlist: Phase 3 Clinical TrialsThe 2nd quarter of 2018 offers investors a number of significant Phase 3 data releases for investors to be aware of before the summer.Apr 13, 2018Apr 13, 2018
Slingshot InsightsWhat to Watch in Q3: Biotech Catalysts — Phase 2 Data Releases (Part 1)2017’s third quarter is packed with important data and regulatory releases with significant potential impacts on pharmaceutical share…Jun 29, 2017Jun 29, 2017
Slingshot InsightsHealthcare Data Releases: What to Watch in 2Q 2017SLINGSHOT INSIGHTS CONTRIBUTOR: Phil LoriaApr 10, 2017Apr 10, 2017
Slingshot InsightsWhat To Watch In Q2: Upcoming Healthcare Regulatory EventsSLINGSHOT INSIGHTS CONTRIBUTOR: Phil LoriaApr 10, 2017Apr 10, 2017
Slingshot InsightsAn Open Letter to the Slingshot Community Regarding Sponsored ContentSlingshot Insights has had an exciting year of growth since launching in December of 2015. During that time our community has grown to over…Mar 6, 2017Mar 6, 2017
Slingshot InsightsSlingshot Insights to host in-depth expert interview on REPH, INSYFollowing success in a Phase 3 trial for bunionectomy surgery this summer, on Nov. 28th Recro Pharma (REPH) released positive Phase 3…Dec 2, 2016Dec 2, 2016
Slingshot InsightsSlingshot Insights Investor Event: Expert Interview on Ophthotech’s FovistaEvent overview:Nov 7, 2016Nov 7, 2016
Slingshot InsightsSlingshot Insights Investor Event: Expert Interview on Scynexis’ SCY-078Event overview:Oct 27, 2016Oct 27, 2016
Slingshot InsightsAlzheimer’s Disease: Market Opportunity And Major Phase 3 Treatments To Know AboutLilly’s (LLY) hotly anticipated Phase 3 data for Alzheimer’s Disease drug solanezumab has left many investors with questions about LLY and…Oct 14, 2016Oct 14, 2016
Slingshot InsightsHealthcare Regulatory Events And Data Releases To Watch In Q4Slingshot Contributor: Phil LoriaOct 5, 2016Oct 5, 2016